SAB Biotherapeutics Business Summary

SAB Biotherapeutics, Inc. (SABS) is a clinical-stage biopharmaceutical company that generates revenue through strategic licensing agreements, government research grants (e.g., BARDA and DoD), and milestone-based partnerships with global pharmaceutical leaders like Sanofi and CSL Behring. The company operates primarily through its Human Polyclonal Immunotherapeutic Antibodies segment, leveraging its proprietary DiversitAb™ platform and transchromosomic cattle (Tc Bovine™) to produce high-potency, fully human polyclonal antibodies (hIgG) without the need for human donors. Its lead clinical candidate, SAB-142, is a disease-modifying therapy for Type 1 Diabetes (T1D) currently in registrational Phase 2b trials. Direct competitors include Rigel Pharmaceuticals, Emergent BioSolutions, Sernova, and Sanofi (via its Provention Bio acquisition). SAB Biotherapeutics distinguishes itself as a market leader in scalable, donor-independent polyclonal therapies, providing a more robust and multi-targeted alternative to traditional monoclonal antibodies and plasma-derived treatments. SAB Biotherapeutics was co-founded by President Eddie J. Sullivan, PhD, a veteran executive with over 25 years of experience who previously led Hematech, a subsidiary of Kyowa Kirin. The leadership team is headed by CEO Samuel J. Reich, who joined in 2024 after serving as Executive Chairman and previously co-founding Biscayne Neurotherapeutics (acquired by Supernus Pharmaceuticals) and leading OPKO Ophthalmologics. The executive suite includes EVP and CFO Lucy To, who brings nearly two decades of investment banking expertise, and EVP and Chief Medical Officer Alexandra Kropotova, MD. In early 2026, the company significantly strengthened its governance by appointing David Zaccardelli, Pharm.D. (former CEO of Verona Pharma), as Chair of the Board and Rita Jain, MD, as an independent director. Notable financial backing includes strategic investment from Sanofi and significant long-term support from billionaire philanthropist T. Denny Sanford.